… Immunotherapy in the form of vaccine or antibody therapy etc. has proved its effectiveness
against viral infectious diseases in earlier cases. Intervention with convalescent plasma from …

… immunotherapy but also as immunotherapy in COVID-19. More studies are needed to assess
the safety of ICI in COVID-19 patients … inhibitors to treat COVID-19 is an option. Table 1 lists …

… immunotherapy treatment pending resolution of viral infection may be a reasonable option
in long-responders patients… In our opinion, all cancer patients treated with immunotherapy …

… hospitalized patients were found to be positive. In conclusion, the outbreak of COVID-19 is
a major worldwide health concern. Our data indicate that COVID-19 mortality in patients with …

… with multiple comorbidities, poor PS, and advanced age; or those infected with SARS-CoV-2
(COVID-19), represent a relatively large proportion of patients in practice for whom we have …

… has a typical framework of cellular profile for patients; for … is no definitive cure for COVID-19
and many people die every day … immunotherapeutic approaches in the treatment of COVID-19…

… with SARS-CoV-2 immunotherapy. Information available in published articles … Covid-19
therapy. Therefore, it is possible saying that immunotherapy is certainly the appropriate option …

… The monoclonal antibodies are the well-recognized passive immunotherapeutic options
in many diseases. This human-made antibody can specifically bind to the designated target, …

… of infection with COVID-19. Indeed, the immune system, which is a main factor in COVID-19 …
We also think it is very significant, and especially with regard to COVID-19, that people who …

… and RCC patient cohorts receiving ICIs throughout the course of the COVID-19 pandemic.
Additional insights regarding the use of ICIs in the setting of current and upcoming COVID-19 …